Free · no card
Get what investors say about MRNA next
1 new call on MRNA this week is not on this page yet. Follow MRNA free and new calls come to you in The Brief, our morning email, the day after we record them. This page shows them a week later.
or continue with Google ·
Who said what, and what MRNA did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
Who’s talking about MRNA
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-10-26 | Barbara DoranCEO & CIO, BD8 Capital Partners | Bullish | Fox Business (uncut) | Personalized mRNA cancer immunotherapy in conjunction with Keytruda trains the immune system to attack cancer… |
| 2026-10-23 | Miles Mentor | Bearish | CNBC (uncut) | Despite genuinely positive melanoma vaccine data (42% risk reduction), MRNA shares are up ~700% YTD so the… |
| 2026-10-22 | Jared HolzManaging Director and Healthcare Equity Strategist, Mizuho | Neutral | CNBC (uncut) | Moderna's cancer-vaccine data were not bad, but expectations were too high and efficacy in other tumor types… |
| 2026-10-21 | Unknown | Bullish | CNBC Fast Money Final Trade | Moderna's strong weekly and daily uptrend could eventually retest 497.49, roughly 50% higher, despite weak… |
| 2026-08-29 | David FriedbergCEO, Ohalo; co-host, All-In | Bearish | All-In Podcast | Moderna's mRNA cancer vaccine moat is weaker than the tripling market cap implies — the neo-antigen… |
Next report: 6 Nov 2026 before the open
Notable options days
Sessions in the last 120 where MRNA’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 10 of 120 sessions qualified.
| Date | Close | RVOL | Δ$ flow ($M) | Call % | LEAPS % | +20 sess. |
|---|---|---|---|---|---|---|
| 2026-10-22 | ||||||
| 2026-09-22 | ||||||
| 2026-08-25 | ||||||
| 2026-08-21 | ||||||
| 2026-08-20 | ||||||
| 2026-08-19 | ||||||
| 2026-08-06 | ||||||
| 2026-06-17 | ||||||
| 2026-06-16 | ||||||
| 2026-06-04 |
MRNA on the Wheel
MRNA did not pass our 1-month put test (V2, V3); the Wheel shows its puts without calling one best.
The Wheel lists cash-secured puts on stocks after a 3% drop, with live quotes, the chance of assignment and each stock’s own history. Free to use; a free account lets you follow stocks, add your own and ask questions.
Decision support, not advice · questions put sellers ask us
Idea Scout
Following MRNA? Every Sunday we read the tape so you don't have to — who's recommending what, where they agree, and who just changed their mind. One free email a week.
Free · double opt-in · unsubscribe in one click